8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE

                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of Earliest Event Reported): February 6, 2002

                               VENTIV HEALTH, INC.

             (Exact Name of Registrant as Specified in its Charter)

                                    DELAWARE
                 (State or Other Jurisdiction of Incorporation)



             0-30318                                     52-2181734
- -------------------------------------       ------------------------------------
     (Commission File Number)               (I.R.S. Employer Identification No.)

                           1114 AVENUE OF THE AMERICAS
                            NEW YORK, NEW YORK 10036
               (Address of Principal Executive offices) (Zip Code)

                                 (212) 768-8000
               (Registrant's Telephone Number, Including Area Code

                                       N/A

          (Former Name or Former Address, if changed Since Last Report)

                               Ventiv Health, Inc.

                           CURRENT REPORT ON FORM 8-K

Item 5. Other Events.

Ventiv Health, Inc. ("Ventiv" or the "Company") has announced via press release
that it has been notified by Reliant Pharmaceuticals, LLC ("Reliant") of their
intent to convert the field sales force working under the Ventiv-Reliant
contract from full-time Ventiv employment to full-time Reliant employment
effective April 1, 2002. The Ventiv-Reliant contract, which commenced on August
1, 2000, provided Reliant with the option to convert all or a portion of the
field sales force to Reliant employment at any time. Revenues from this client
relationship represented 21.6% of the Company's total revenues for the
nine-month period ended September 30, 2001.

Item 7. Financial Statements and Exhibits

(c) Exhibits

99.1 Press release of Ventiv Health, Inc., dated as of February 5, 2002.



                                                              SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                              VENTIV HEALTH, INC.


                              By: /s/ John R. Emery

                                  --------------------------------------------
Date: February 6, 2002            Name: John R. Emery
                                   Title: Chief Financial Officer
                                   (Principal Accounting and Financial Officer)

EX-99.1

                                                                    EXHIBIT 99.1

[VENTIV LOGO]

Contacts:
Investors/Corporate:                                 Media:
John R. Emery                                        Lynn Blenkhorn
Chief Financial Officer                              Noonan/Russo Communications
(732) 537-4800                                       (212) 696-4455
investor@ventiv.com                                  Media@ventiv.com
- -------------------                                  -----------------



 VENTIV HEALTH, INC. ANNOUNCES CONVERSION OF RELIANT PHARMACEUTICALS SALES FORCE

NEW YORK, February 5, 2002 -- Ventiv Health, Inc. (Nasdaq:VTIV), a leading
provider of comprehensive marketing and sales solutions to the pharmaceutical
and life sciences industries, announced today it has been notified by Reliant
Pharmaceuticals, LLC, of Reliant's intent to convert the field sales force
working under the Ventiv-Reliant contract from full-time Ventiv employment to
full-time Reliant employment effective April 1, 2002. The Ventiv-Reliant
contract, which commenced on August 1, 2000, provided Reliant with the option to
convert all or a portion of the field sales force to Reliant employment at any
time. Ventiv will work with Reliant to ensure the conversion is implemented
smoothly.

Mr. Eran Broshy, President and CEO of Ventiv, said "As with many of our
contracts, we have always known that conversion of the Reliant sales force was a
possibility. We are pleased we were able to help Reliant develop its
commercialization infrastructure during the past 18 months."

Mr. Joseph Krivulka, President of Reliant Pharmaceuticals, stated "The level of
service provided by Ventiv during the past 18 months helped us to reach this
important milestone in Reliant's history. We appreciate Ventiv's contribution to
our company's current and future success."

On February 28, 2002, Ventiv plans to announce its results for the quarter and
year ended December 31, 2001. At that time, Ventiv will also provide guidance on
its financial outlook for the remainder of 2002, which will incorporate the
termination of the Reliant contract, as well as other current and anticipated
developments.

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation:
changes in trends in the pharmaceutical industry or in pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market; our ability to maintain large client contracts or to enter into new
contracts; uncertainties related to future incentive payments and revenue share
agreements; and, our ability to operate successfully in new lines of business.
Readers of this press release are referred to documents filed from time to time
by Ventiv Health, Inc. with the Securities and Exchange Commission for further
discussion of these and other factors.